Finding new treatments for bone cancer using patient-derived models
Official title: Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models
Funded at University of Tx Md Anderson Can Ctr · NIH-11121898 · Data updated 2026-11-12
This work looks for new ways to treat osteosarcoma, a type of bone cancer, especially in children and young adults, by testing promising new medicines.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 10, 2015 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $405,000 |
| NIH project number | 5U01CA199221-11 |
| Project ID | NIH-11121898 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational work is for patients with osteosarcoma, particularly children, adolescents, and young adults, whose tumors may provide insights for new therapies.
✕Less likely to help
Patients without osteosarcoma or those whose cancer does not match the specific molecular targets being studied may not directly benefit from this particular research.
What this research studies
For patients with osteosarcoma, current treatments haven't changed much in decades, making it hard to find new effective options. Our team is working to discover new targets in osteosarcoma by carefully studying patient-derived cancer cells and tissues. We then test potential new medicines against these targets in models that closely resemble human tumors. The goal is to find effective single agents or combinations that can move into clinical trials for patients.
Why it matters
Potential benefit: If successful, this work could lead to new, more effective treatment options for children and young adults with osteosarcoma.
How similar studies have gone: Developing new therapies for osteosarcoma has been challenging, but this approach builds on existing methods of genomic profiling and preclinical testing to identify promising agents.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Gorlick, Richard G. — University of Tx Md Anderson Can Ctr
- Study coordinator: Gorlick, Richard G.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.